Advertisement

Advertisement

News

MET-Driven Kidney Cancer: Combination of Durvalumab and Savolitinib Under Study

News

Checking Checkpoint Inhibitor Effectiveness in Immunocompromised Patients With Advanced Skin Cancer

Medical Literature

Adding Stereotactic Body Radiotherapy to Immunotherapy for Early-Stage NSCLC

Medical Literature

Does Ibrutinib Pretreatment Reduce the Risk of Obinutuzumab-Related Infusion Reactions in CLL?

News

Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC?

News

Updated Survival Outcomes From PACIFIC Trial of Immunotherapy for Stage III Lung Cancer

Medical Literature

Medicare-Insured Patients With Advanced Lung Cancer: Does First-Line Immunotherapy Improve Survival?

Karl D. Lewis, MD, on the Role of Adjuvant Immunotherapy in NMSC

Thierry André, MD, on KEYNOTE-177: Clinical Implications of Pembrolizumab vs Chemotherapy in Metastatic Colorectal Cancer

View More

Advertisement

JNCCN Spotlights

(UPDATE) Daratumumab (MM)

(UPDATE) Pertuzumab (Breast Cancer)

View More

More

News

ASCO 2021: Converting Peripheral Blood Mononuclear Cells Into Autologous Cellular Therapy for CLL

Patient With Breast Cancer Successfully Treated With Immunotherapy in Thailand Hospital

Choice of Platinum in First Line Treatment of Advanced Urothelial Carcinoma in the Era of Second-Line Immunotherapy

ASCO 2021: Early-Phase Results of Anti-CLL1–Based CAR T-Cell Therapy in Children With AML

Lenvatinib Plus Pembrolizumab in Renal Cell Carcinoma: Phase IB/II Trial Results

Perioperative Use of Cemiplimab Under Study in Cutaneous Squamous Cell Carcinoma

FDA Brief: Eprenetapopt Given Fast Track Designation for TP53-Mutant AML

Mixed Results With Rucaparib in ATLAS Trial in Metastatic Urothelial Cancer

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

High-Rick Relapsing MM: Retreatment With Immunomodulatory Therapy

JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

View More

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

Center for Immunotherapy Clinical Research Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

ClinicalTrials.gov Immunotherapy

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.